MD Anderson Cancer Center
Oncology
Dr. Naoto Ueno, MD
|
|
Give Review
Dr. Naoto Ueno works in the field of Oncology. Naoto Ueno is a published doctor as well. He has 66 publications published. The latest was: MicroRNA expression profiling identifies decreased expression of miR-205 in inflammatory breast cancer. He accepts Medicare.
Publications
- Epidemiological risk factors associated with inflammatory breast Cancer subtypes.
- MicroRNA expression profiling identifies decreased expression of miR-205 in inflammatory breast Cancer.
- Simvastatin prevents triple-negative breast Cancer metastasis in pre-clinical models through regulation of FOXO3a.
- Circulating Tumor Cells and Recurrence After Primary Systemic Therapy in Stage III Inflammatory Breast Cancer.
- Has Racial Difference in Cause-Specific Death Improved in Older Patients with Late-Stage Breast Cancer?
- Overall survival differences between patients with inflammatory and noninflammatory breast Cancer presenting with distant metastasis at diagnosis.
- Is the future of personalized therapy in triple-negative breast Cancer based on molecular subtype?
- Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials.
- Disulfiram (DSF) acts as a copper ionophore to induce copper-dependent oxidative stress and mediate anti-tumor efficacy in inflammatory breast Cancer.
- Circulating tumor cells in newly diagnosed inflammatory breast Cancer.
- Mesenchymal stem cells mediate the clinical phenotype of inflammatory breast Cancer in a preclinical model.
- High-density and very-low-density lipoprotein have opposing roles in regulating tumor-initiating cells and sensitivity to radiation in inflammatory breast Cancer.
- Functional consequence of the MET-T1010I polymorphism in breast Cancer.
- Challenging a traditional paradigm: 12-year experience with autologous free flap breast reconstruction for inflammatory breast Cancer.
- Development of PEA-15 using a potent non-viral vector for therapeutic application in breast Cancer.
- Targeted therapies in triple-negative breast Cancer: failure and future.
- Circulating tumour cells are linked to plasma D-dimer levels in patients with metastatic breast Cancer.
- Reverse-phase protein array for prediction of patients at low risk of developing bone metastasis from breast Cancer.
- Clinical Characteristics and Outcome of Bone-Only Metastasis in Inflammatory and Noninflammatory Breast Cancers.
- Gene Signature-Guided Dasatinib Therapy in Metastatic Breast Cancer.
- Underuse of Trimodality Treatment Affects Survival for Patients With Inflammatory Breast Cancer: An Analysis of Treatment and Survival Trends From the National Cancer ...
- A class I histone deacetylase inhibitor, entinostat, enhances lapatinib efficacy in HER2-overexpressing breast Cancer cells through FOXO3-mediated Bim1 expression.
- Simvastatin Radiosensitizes Differentiated and Stem-Like Breast Cancer Cell Lines and Is Associated With Improved Local Control in Inflammatory Breast Cancer Patients ...
- Antagonism of Tumoral Prolactin Receptor Promotes Autophagy-Related Cell Death.
- Expression of androgen receptor in inflammatory breast Cancer and its clinical relevance.
- Primary tumor resection as a component of multimodality treatment may improve local control and survival in patients with stage IV inflammatory breast Cancer.
- Breast Cancer Biomarkers: Utility in Clinical Practice.
- Aldehyde Dehydrogenase 1 Expression in Inflammatory Breast Cancer as Measured by Immunohistochemical Staining.
- TIG1 Promotes the Development and Progression of Inflammatory Breast Cancer through Activation of Axl Kinase.
- Differential response to neoadjuvant chemotherapy among 7 triple-negative breast Cancer molecular subtypes.
- Statin use in primary inflammatory breast Cancer: a cohort study.
- (18)F-FDG PET/CT predicts survival in patients with inflammatory breast Cancer undergoing neoadjuvant chemotherapy.
- Genomic and expression analysis of microdissected inflammatory breast Cancer.
- Bisphosphorylated PEA-15 Sensitizes Ovarian Cancer Cells to Paclitaxel by Impairing the Microtubule-Destabilizing Effect of SCLIP.
- Allogeneic hematopoietic Cell transplantation for neuroblastoma: the CIBMTR experience.
- Ink4a/Arf(-/-) and HRAS(G12V) transform mouse mammary cells into triple-negative breast Cancer containing tumorigenic CD49f(-) quiescent cells.
- Adding hormonal therapy to chemotherapy and trastuzumab improves prognosis in patients with hormone receptor-positive and human epidermal growth factor receptor 2-posi...
- Epithelial-Mesenchymal Transition and Stem Cell Markers in Patients with HER2-Positive Metastatic Breast Cancer.
- Role of epidermal growth factor receptor in breast Cancer.
- A Prospective Study of Bone Tumor Response Assessment in Metastatic Breast Cancer.
- Histone Deacetylase Inhibitors Stimulate Dedifferentiation of Human Breast Cancer Cells Through WNT/beta-Catenin Signaling.
- Prognostic Value of EMT-Circulating Tumor Cells in Metastatic Breast Cancer Patients Undergoing High-Dose Chemotherapy with Autologous Hematopoietic Stem Cell Transpla...
- Relationship Between Lymphocytopenia and Circulating Tumor Cells as Prognostic Factors for Overall Survival in Metastatic Breast Cancer.
- Metastasis in the Breast Mimicking Inflammatory Breast Cancer.
- Inflammatory breast Cancer: what we know and what we need to learn.
- Pretreatment staging positron emission tomography/computed tomography in patients with inflammatory breast Cancer influences radiation treatment field designs.
- Retrospective analysis of antitumor effects of zoledronic acid in breast Cancer patients with bone-only metastases.
- Estrogen Receptor (ER) mRNA and ER-Related Gene Expression in Breast Cancers That Are 1% to 10% ER-Positive by Immunohistochemistry.
- Loss of Human Epidermal Growth Factor Receptor 2 (HER2) Expression in Metastatic Sites of HER2-Overexpressing Primary Breast Tumors.
- MEK 1/2 Inhibitor selumetinib (AZD6244) Inhibits Growth of Ovarian Clear Cell Carcinoma in a PEA-15-dependent Manner in a Mouse Xenograft Model.
- Triple-Negative Subtype Predicts Poor Overall Survival and High Locoregional Relapse in Inflammatory Breast Cancer.
- Polycomb group protein EZH2 is frequently expressed in inflammatory breast Cancer and is predictive of worse clinical outcome.
- FDG-PET/CT Compared with Conventional Imaging in the Detection of Distant Metastases of Primary Breast Cancer.
- High-dose chemotherapy with autologous stem-cell support as adjuvant therapy in breast Cancer: overview of 15 randomized trials.
- High-dose chemotherapy with autologous hematopoietic stem-cell transplantation in metastatic breast Cancer: overview of six randomized trials.
- Gemcitabine Overcomes Erlotinib Resistance in EGFR-Overexpressing Cancer Cells through Downregulation of Akt.
- Targeting EGFR in Triple Negative Breast Cancer.
- Association of Body Mass Index Changes during Neoadjuvant Chemotherapy with Pathologic Complete Response and Clinical Outcomes in Patients with Locally Advanced Breast...
- cMET Activation and EGFR-Directed Therapy Resistance in Triple-Negative Breast Cancer.
- The role of inflammation in inflammatory breast Cancer.
- Predictors of durable no evidence of disease status in de novo metastatic inflammatory breast Cancer patients treated with neoadjuvant chemotherapy and post-mastectomy...
- High serum miR-19a levels are associated with inflammatory breast Cancer and are predictive of favorable clinical outcome in patients with metastatic HER2+ inflammator...
- Status of the anaplastic lymphoma kinase (ALK) gene in inflammatory Breast carcinoma.
- The antihelmintic drug pyrvinium pamoate targets aggressive breast Cancer.
- Inflammatory breast Cancer: the disease, the biology, the treatment.
Procedures Preformed
- Cardiac MRI (Magnetic Resonance Imaging) of Heart or Chest
- HPC Transplantation (Stem Cell Transplant)
Conditions Treated
- Acute Leukemia
- Adrenal Gland Cancer
- Anemia
- Brain and Nervous System Cancer (incl. Gliomas, Astrocytoma, Schwannoma, Medulloblastoma, Chordoma)
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Education
-
University of Texas Health Science Center -
University of Pittsburgh Medical Center
Hospital
-
University of Texas M.D. Anderson Cancer Center
Drug Facts
| NPI NUMBER | 1851497770 | |
| NPPES Provider LastName | UENO | |
| NPPES Provider FirstName | NAOTO | |
| NPPES Provider ZIPCode | 770304009 | |
| NPPES Provider State | TX | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 171.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 15.0 | |
| Percent Opioid Claims | 8.77 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1851497770 |
| Last Name Of The Provider | UENO |
| First Name Of The Provider | NAOTO |
| View All |
Similar Doctors
|
|
Dr. Andrea L. Dean, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Tapan M. Kadia, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Robert S. Benjamin, MD |
|
|
Dr. Banu K. Arun, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sheridan M. Diaz, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Muzaffar H. Qazilbash, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Pierre Saintigny, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. John V. Heymach, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Karin Hahn, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Dongxin Liu, MD
This Doctor is OpenDoctor Recommended.
|